Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
558actual
Sites
76
Countries
Canada, Germany, Japan +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-22 | actual | When the study began enrolling |
| Primary completion | 2026-01-12 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-15 | actual | The whole study's end, after follow-up |
| First posted | 2024-08-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Neuropathic Pain
- Distal Sensory Polyneuropathy
Interventions
- Drug: LY3848575
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFMean Change from Baseline in Average Pain Intensity Numeric Rating Scale (API-NRS)
measured Baseline, Week 12
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed